| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
Diabody (bispecific antibody) that controls the function of HIV-Nef for novel medical treatment of AIDS based on the new concept has been developed by combination of anti-myristoyl group antibody, anti-HIV-Nef antibody, and a molecular needle for entry into cells. By allowing this artificial diabody to act on AIDS infected T cells into which HIV-Nef has been introduced, inhibition of T cell function by HIV-Nef is prevented.
Anti-HIV-Nef antibody and anti-myristoylation group antibody have been succeeded in developing by original antibody library technology. We also succeeded in fusing a phage-derived molecular needle to the anti-HIV-Nef antibody.
The future issue is whether the artificial antibody created this time can restore the function of HIV-infected T cells.
|
